203 related articles for article (PubMed ID: 23528371)
1. PTCL therapies: a review of treatment and outline of novel therapies.
Khan N; Cheson BD
Am J Ther; 2013; 20(5):524-33. PubMed ID: 23528371
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
[TBL] [Abstract][Full Text] [Related]
3. Enhancing existing approaches to peripheral T-cell lymphoma.
Foss FM
Semin Hematol; 2010 Apr; 47 Suppl 1():S8-10. PubMed ID: 20359584
[TBL] [Abstract][Full Text] [Related]
4. Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?
Lunning MA; Horwitz S
Curr Treat Options Oncol; 2013 Jun; 14(2):212-23. PubMed ID: 23568456
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma.
d'Amore F; Radford J; Relander T; Jerkeman M; Tilly H; Osterborg A; Morschhauser F; Gramatzki M; Dreyling M; Bang B; Hagberg H
Br J Haematol; 2010 Sep; 150(5):565-73. PubMed ID: 20629661
[TBL] [Abstract][Full Text] [Related]
6. Novel agents in development for peripheral T-cell lymphoma.
O'Connor OA
Semin Hematol; 2010 Apr; 47 Suppl 1():S11-4. PubMed ID: 20359580
[TBL] [Abstract][Full Text] [Related]
7. Novel targeted therapies in peripheral T cell lymphoma.
Jagadeesh D; Smith MR
Discov Med; 2013 Jun; 15(85):367-78. PubMed ID: 23819951
[TBL] [Abstract][Full Text] [Related]
8. Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma.
Marchi E; Raufi AG; O'Connor OA
Hematol Oncol Clin North Am; 2017 Apr; 31(2):359-375. PubMed ID: 28340883
[TBL] [Abstract][Full Text] [Related]
9. New drug therapies in peripheral T-cell lymphoma.
Howman RA; Prince HM
Expert Rev Anticancer Ther; 2011 Mar; 11(3):457-72. PubMed ID: 21417858
[TBL] [Abstract][Full Text] [Related]
10. Treatment strategies for peripheral T-cell lymphomas.
Foss FM
Best Pract Res Clin Haematol; 2013 Mar; 26(1):43-56. PubMed ID: 23768640
[TBL] [Abstract][Full Text] [Related]
11. Peripheral T-cell lymphoma: new therapeutic strategies.
Petrich AM; Rosen ST
Oncology (Williston Park); 2013 Sep; 27(9):878-84. PubMed ID: 24282984
[TBL] [Abstract][Full Text] [Related]
12. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas.
Zinzani PL; Bonthapally V; Huebner D; Lutes R; Chi A; Pileri S
Crit Rev Oncol Hematol; 2016 Mar; 99():214-27. PubMed ID: 26811013
[TBL] [Abstract][Full Text] [Related]
13. Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management.
Zain JM
Am J Hematol; 2019 Aug; 94(8):929-946. PubMed ID: 31119775
[TBL] [Abstract][Full Text] [Related]
14. The potential of pralatrexate as a treatment of peripheral T-cell lymphoma.
Dondi A; Bari A; Pozzi S; Ferri P; Sacchi S
Expert Opin Investig Drugs; 2014 May; 23(5):711-8. PubMed ID: 24661228
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.
Kim SJ; Yoon DH; Kang HJ; Kim JS; Park SK; Kim HJ; Lee J; Ryoo BY; Ko YH; Huh J; Yang WI; Kim HK; Min SK; Lee SS; Do IG; Suh C; Kim WS;
Eur J Cancer; 2012 Nov; 48(17):3223-31. PubMed ID: 22770877
[TBL] [Abstract][Full Text] [Related]
16. Management of advanced-stage peripheral T-cell lymphomas.
Kimby E
Curr Hematol Malig Rep; 2007 Oct; 2(4):242-8. PubMed ID: 20425376
[TBL] [Abstract][Full Text] [Related]
17. Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development.
Chen AI; Advani RH
J Natl Compr Canc Netw; 2008 Apr; 6(4):428-35. PubMed ID: 18433608
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapeutic advancements in peripheral T-cell lymphoma.
Reddy NM; Evens AM
Semin Hematol; 2014 Jan; 51(1):17-24. PubMed ID: 24468312
[TBL] [Abstract][Full Text] [Related]
19. Current treatment and future prospects for peripheral T-cell lymphoma.
Eyre TA; Collins GP
Drugs Today (Barc); 2013 Oct; 49(10):631-46. PubMed ID: 24191256
[TBL] [Abstract][Full Text] [Related]
20. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]